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2054intensiﬁcation and individualization of their cardiac care. The
ﬁnding that event rates were similarly low in the intensiﬁed group
and in patients who had low NP levels and were not included in the
study cannot apparently speak against this because the PONTIAC
trial was not designed or powered to address this comparison (4).
Thus, why not follow a similar “intensiﬁed” and individualized
approach in all patients with DM? Cost analysis studies are
required to address whether such an approach is cost-effective.
Even in the ﬁeld of heart failure, where NPs are excellent
diagnostic and prognostic tools, there is still conﬂicting evidence
regarding their effectiveness to guide therapy; it seems that they
are of beneﬁt only when used in the context of a multidisciplinary
approach. Given that DM is currently considered a coronary artery
disease equivalent, the key to CV prevention in these patients
could be the close multidisciplinary follow-up, the individualization
of treatment, and the sufﬁcient use of health care resources. NPs or
other biomarkers may be of help as part of such an approach.Dimitrios Farmakis, MD
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Diabetes Mellitus
No Magic Remedies
We fully agree that the PONTIAC (NT-proBNP Guided Primary
Prevention of CV Events in Diabetic Patients) trial raises more
than a few new questions (1).
As mentioned by Dr. Farmakis and colleagues, most trials
conducted in patients with diabetes have been unsuccessful inreducing cardiovascular events. We agree that this might be based
at least in part on the wrong patient selection, which is an issue that
has been discussed before. The risk markers used in those studies
are inferior to N-terminal pro–B-type natriuretic peptide (NT-
proBNP), which was comprehensively proven prospectively (2,3)
and twice conﬁrmed recently.
In this context, we believe that we can learn even more from
the ROADMAP (Randomized Olmesartan and Diabetes Micro-
albuminuria Prevention) trial than from the points mentioned by
Dr. Farmakis and colleagues. The results of that trial were indeed
remarkable; the investigators found a delay in the worsening of
proteinuria not only at the cost of minor side effects such as hy-
potension but also with a small but signiﬁcant increase in fatal
cardiovascular events. The study was long withheld due to this
unexplainable result, similar to the REVIVE (Randomized Evalu-
ations of Levosimendan) study. We have to be aware that treatment
in low-risk patients might not only be inefﬁcient; oversuppression
of essential pathways (e.g., of the renin-angiotensin system [RAS])
can actually be harmful.
The second insight we have gained from the ROADMAP trial is
that the treatment of surrogates of outcome, such as proteinuria,
does not necessarily result in a survival beneﬁt. Others have already
called for not treating the marker but instead the system (4). This
has to be kept in mind when we interpret the unexpected lack
of a decrease in NT-proBNP levels, which was noted in the
PONTIAC and STOP-HF (St. Vincent’s Screening To Prevent
Heart Failure) trials (5). We did not intend to treat NT-proBNP,
but instead attempted to understand this marker primarily as a
surrogate for risk. The underlying cause of increased NT-proBNP
levels is not well understood. It can be assumed that activation of
the RAS and the adrenergic system are responsible for this phe-
nomenon. However, as noted by Dr. Farmakis and colleagues, a
decrease in kidney function might also be a possible reason. In this
case, an RAS antagonist would also be a valid treatment option.
Regarding risk, we believe there is no such thing as a false-positive
or negative result. Lower levels of NT-proBNP in highly-obese
people or increased levels in kidney disease directly translate into a
different risk proﬁle.
The concern that the effect of the PONTIAC trial is based
on care is probably not valid because the difference in the number
of visits only averaged 1.3. Unlike the STOP-HF trial, visits to our
treatment center did not lead to a change in diagnostic workup or
decisions about hospitalization, as stated in our report.
A decrease in glomerular ﬁltration rate after up-titration is a
common and clinically-negligible phenomenon, which has already
been extensively proven and discussed (6).
Finally, we agree that our results are not deﬁnitive. Further
studies are needed to prove whether our approach might be a way to
select patients who will beneﬁt from therapy.*Richard Pacher, MD
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Myocardial Scar in
Atrial Fibrillation
Neilan et al. (1) have investigated the prognostic role of left
ventricular myocardial scar in patients with atrial ﬁbrillation and
noted that the presence of late gadolinium enhancement (LGE)
predicts mortality compared with the absence of LGE. It would
be interesting to know whether the mortality differs according to
the type (transmural, subendocardial, and nonmyocardial) and
the extent of LGE, because the presence of transmural
enhancement has been shown to be associated with heart failure
compared with nontransmural enhancement (2). Neilan et al. (1)
also noted that, in patients with atrial ﬁbrillation referred for
cardiac magnetic resonance, the presence of LGE predicts
mortality compared with the absence of LGE. Atrial ﬁbrillation
(3) and the presence of LGE (4) have been shown to predict
mortality. It would be interesting to know whether the presence
of LGE has any incremental prognostic value in patients with
atrial ﬁbrillation.*Arun Kannan, MD
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Myocardial Scar in
Atrial Fibrillation
We thank Drs. Kannan and Balamuthusamy for their interest in
our report (1) and appreciate the opportunity to reply. Among our
entire cohort of 720 patients, 44 of the 108 cases of abnormal late
gadolinium enhancement (LGE) were non–infarct-appearing LGE
(epicardial, midmyocardial, or patchy) and 64 cases were infarct
appearing (Table 2 in our report). Thus, in our observation cohort,
infarct-appearing LGE was the dominant factor that accounted for
the prognostic association between LGE and mortality in patients
with atrial ﬁbrillation referred for cardiac magnetic resonance. In
our subanalysis with patients with infarct LGE excluded, as shown
in Table 5 in our report, non–infarct-appearing LGE also showed
a strong association with mortality (hazard ratio: 4.21; p < 0.0001).
Therefore, based on our experience, patients with atrial ﬁbrillation
referred for cardiac magnetic resonance may have LGE as a result
of either infarction or noncoronary pathology, and both of these
ﬁndings portend an elevated risk of mortality. Regarding the
different patterns of noninfarct LGE (epicardial, midmyocardial,
or patchy), our study was not designed or powered to assess their
respective prognostic associations with patient mortality.*Tomas G. Neilan, MD
Raymond Y. Kwong, MD, MPH
*Division of Cardiology
Department of Medicine
Cardiac MR PET CT Program
Department of Radiology
Massachusetts General Hospital
55 Fruit Street
VBK-508
Boston, Massachusetts 02114
E-mail: tneilan@partners.org
http://dx.doi.org/10.1016/j.jacc.2014.01.027
REFERENCE
1. Neilan TG, Shah RV, Abbasi SA, et al. The incidence, pattern, and
prognostic value of left ventricular myocardial scar by late gadolinium
enhancement in patients with atrial ﬁbrillation. J Am Coll Cardiol 2013;
62:2205–14.
